Royalty Pharma (RPRX) said Wednesday that it has agreed to provide Biogen (BIIB) with up to $250 million in research and development funding for drug candidate litifilimab to potentially treat systemic lupus erythematosus and cutaneous lupus erythematosus.
The company said it will provide the funding over six quarters in exchange for regulatory milestones and mid-single digit royalties on annual worldwide sales.
Litifilimab is currently in phase 3 trials, with results expected between 2026 and 2027, Royalty Pharma said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.